[Modern drug therapy in cardiovascular intensive care medicine].

about

[Modern drug therapy in cardiovascular intensive care medicine].

Item

http://www.wikidata.org/entity/Q39188101

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

[Modern drug therapy in cardiovascular intensive care medicine].

@en

[Modern drug therapy in cardiovascular intensive care medicine].

@nl

type

Item

label

[Modern drug therapy in cardiovascular intensive care medicine].

@en

[Modern drug therapy in cardiovascular intensive care medicine].

@nl

prefLabel

[Modern drug therapy in cardiovascular intensive care medicine].

@en

[Modern drug therapy in cardiovascular intensive care medicine].

@nl

P1476

[Modern drug therapy in cardiovascular intensive care medicine]

@en

P2093

M Buerke

http://www.w3.org/2001/XMLSchema#string

M Janusch

http://www.w3.org/2001/XMLSchema#string

S Dietz

http://www.w3.org/2001/XMLSchema#string

P2860

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

Effect of nesiritide in patients with acute decompensated heart failure

The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.

Relaxin: review of biology and potential role in treating heart failure.

Cardiac myosin activation part 1: from concept to clinic.

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

P304

702, 704-8, 710-2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00108-015-3717-9

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Henning Lemm

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26054838

http://www.w3.org/2001/XMLSchema#string